Natural Supplements & Vitamins Blog

SAN JOSE, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) — The Santa Clara County Board of Supervisors unanimously declared Lyme Disease Awareness in the County. The proposal, put forward by Supervisor Dave Cortese, brings a heightened and renewed focus on a growing public health crisis in the County. On May 13, the Santa Clara County also promoted National Lyme Disease Awareness Month and the Center for Disease Control’s “Tick Lunch and Learn Series” on the County’s social media presence. “With our belief that being outside is safer than being inside in preventing COVID-19 transmissions, it is important that we call attention to...

– Wendy Adams, Research Grant Director, Bay Area Lyme Foundation Erythema migrans (EM) is the hallmark sign of infection with B. burgdorferi. An EM is defined as an expanding annular (round) lesion or rash of at least 10cm (2.5in). Most rashes occur 3–30 days after infection, however there are case reports that show EMs can appear sooner than three days post infection. The term “Bulls-eye” rash is often used synonymously with EM. But an EM is not required to have central clearing or a target appearance. The rash can take many forms, and may have a raised bump in the middle, can...

FOR IMMEDIATE RELEASE Media Contact: Tara DiMilia, 908-947-0500, This email address is being protected from spambots. You need JavaScript enabled to view it. Jacob Lemieux, MD, DPhil and Artem Rogovskyy, DVM, PhD Named Recipients of Bay Area Lyme Foundation’s 2020 Emerging Leader Award Biobank Samples to Aid 2020 Emerging Leader Award Winners in Discovery of New Rapid and Sensitive Diagnostics for Lyme Disease Testing PORTOLA VALLEY, Calif., August 11, 2020 — Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., announces the recipients of the 2020 Emerging Leader Awards, which are designed to support promising scientists who represent the future of Lyme disease-research leadership. Jacob Lemieux, MD, DPhil of Harvard and...

Jacob Lemieux, MD, PhD (Harvard/MIT Broad Institute)Bay Area Lyme’s 2020 Emerging Leader Award Winner, Jacob Lemieux, MD, PhD, of the Harvard/MIT Broad Institute, discusses Borrelia and malaria, next-generation sequencing, COVID-19, and Lyme diagnostic challenges. Original linkOriginal author: Bay Area Lyme Foundation

Artem Rogovsky, PhD (Texas A & M) Bay Area Lyme’s 2020 Emerging Leader Award Winner, Artem Rogovsky, PhD, of the Department of Veterinary Pathobiology, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, discusses radioactive ticks, Lyme diagnostics, and how a kid’s birthday party can lead to novel research. Original linkOriginal author: Bay Area Lyme Foundation

Liz Horn, PhD, MBI (Lyme Disease Biobank) Principal Investigator for the Bay Area Lyme Disease Biobank, Liz Horn, PhD, MBI, discusses the Biobank which has enrolled over 900 participants, supporting 50 research projects so far. They support research projects across the nation by providing precious serum, whole blood, urine and tissue samples to researchers. Original linkOriginal author: Bay Area Lyme Foundation

– Wendy Adams, Research Grant Director, Bay Area Lyme Foundation This pandemic has brought many different modalities in diagnostics, drug development and vaccines to the popular press. In the Tick-borne Disease (TBD) community, we have seen the issues that arise when the timely diagnosis and treatment of infectious disease are hampered by insensitive diagnostics and ineffective treatments. It bears repeating however, that drugs that fight the infection in question (antibiotics, antiparasitics, or antivirals) are a large part of any eventual solution to an outbreak, especially in advance of a vaccine (see HIV). Antimicrobial therapeutics help keep the pathogen from replicating uncontrolled,...

FOR IMMEDIATE RELEASE Media Contact: Tara DiMilia, 908-947-0500, This email address is being protected from spambots. You need JavaScript enabled to view it. Lyme Disease Biobank Expands Into San Diego Legislative Commendations Support Importance of New Collection Site’s Efforts To Elevate Research San Diego, CA, March 6, 2020—Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., announces the opening of the San Diego collection site of the Bay Area Lyme Foundation’s Lyme Disease Biobank, which is the first program to provide researchers with blood and urine samples from people with early Lyme disease from multiple endemic regions across the country. Congressman Scott Peters and Council member Chris Cate are scheduled to...

FOR IMMEDIATE RELEASE Media Contact: Tara DiMilia, 908-947-0500, This email address is being protected from spambots. You need JavaScript enabled to view it. New Study Shows Less Than One-Third of Lyme Disease Test Results are Accurate for Patients with Lyme Rash Journal of Clinical Microbiology Publishes Lyme Disease Biobank Data Describing Samples Available for Research on Tick-Borne Infections Portola Valley, Calif., February 26, 2020—Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., announces results published in the Journal of Clinical Microbiology, a journal of the American Society for Microbiology, that point to limitations of currently available diagnostic tests for early-stage Lyme disease and highlight the need for more research toward improved...

FOR IMMEDIATE RELEASE Media Contact: Tara DiMilia, 908-947-0500, This email address is being protected from spambots. You need JavaScript enabled to view it. Seven Herbal Medicines Are Capable of Killing Lyme Disease Bacteria, According to New Lab Study Research Supported by Bay Area Lyme Foundation Evaluates Anti-microbial Effects of 14 Natural Products Compared to Antibiotics Used to Treat Lyme Disease Marin, CA, February 21, 2020—Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., today announced the publication of new data finding that seven herbal medicines are highly active in test tubes against B. burgdorferi, the bacteria that causes Lyme disease, compared to the control antibiotics, doxycycline and cefuroxime. Published in the...

FOR IMMEDIATE RELEASE Media Contact: Tara DiMilia, 908-947-0500, This email address is being protected from spambots. You need JavaScript enabled to view it. Bay Area Lyme Foundation Highlights 2019 Progress toward Diagnosing, Treating and Preventing Lyme Disease Bay Area Lyme Foundation has now funded more than 100 research projects at 38 institutions around the country since its inception in 2012 PORTOLA VALLEY, Calif., December 13, 2019—Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., today announced an exceptional year in research, including the first published studies using samples from the Lyme Disease Biobank and advances in research of disulfiram for treating individuals suffering from chronic Lyme disease and chronic babesiosis, an approach...

Guest Post fromMichelle McKeon, MSPresident, Lyme and Cancer Services Bay Area Lyme is happy to share the editorial contributions of care providers, patients, caregivers, and others in the community who are eager to share their knowledge for the benefit of others suffering from Lyme and related tick-borne illnesses. There is still so much we don’t know and so much we are just learning. It is critical that we keep an active dialogue and share and collaborate to continue to move our understanding forward. What follows is an article written by a guest contributor and practicing care provider who shares that view...

FOR IMMEDIATE RELEASE Media Contact: Tara DiMilia, 908-947-0500, This email address is being protected from spambots. You need JavaScript enabled to view it. Journal of Clinical Microbiology Publishes First Study Using Samples from the Lyme Disease Biobank More Than 40 Research Projects Have Now Used Samples from Bay Area Lyme Foundation’s Lyme Disease Biobank PORTOLA VALLEY, Calif., Oct. 15, 2019 /PRNewswire/—Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., today announced that a study published in the Journal of Clinical Microbiology reports a potential new diagnostic, mChip-Ld, which can be performed in 15 minutes in a physician’s office, offers efficacy improvement over the current gold standard diagnostic, the two-tier test, and may be...